A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Summary SGN‐30, a chimeric anti‐CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). We conducted an open‐label, Phase II study to determine the safety and objective response rate of SGN‐30 in 79 pa...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	British journal of haematology Ročník 146; číslo 2; s. 171 - 179
Hlavní autori:	Forero‐Torres, Andres, Leonard, John P., Younes, Anas, Rosenblatt, Joseph D., Brice, Pauline, Bartlett, Nancy L., Bosly, Andre, Pinter‐Brown, Lauren, Kennedy, Dana, Sievers, Eric L., Gopal, Ajay K.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Oxford, UK Blackwell Publishing Ltd 01.07.2009 Blackwell
Predmet:	Adult Aged anaplastic large cell lymphoma anaplastic lymphoma kinase Antibodies, Anti-Idiotypic - blood Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antineoplastic Agents - administration & dosage anti‐CD30 antibody Biological and medical sciences Chimerin Proteins - blood Dose-Response Relationship, Drug Female Hematologic and hematopoietic diseases Hodgkin Disease - therapy Hodgkin lymphoma Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, Large-Cell, Anaplastic - drug therapy Male Medical sciences Middle Aged monoclonal antibody Young Adult Hematology anti-CD30 antibody Anaplastic cell lymphoma Hodgkin disease Malignant hemopathy Large cell lymphoma Monoclonal antibody Non Hodgkin lymphoma Treatment Lymphoproliferative syndrome Phase II trial anaplastic large cell lymphoma Anaplastic lymphoma kinase Cancer Hodgkin lymphoma
ISSN:	0007-1048, 1365-2141, 1365-2141
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Summary SGN‐30, a chimeric anti‐CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). We conducted an open‐label, Phase II study to determine the safety and objective response rate of SGN‐30 in 79 patients with refractory/recurrent HL (n = 38) or systemic ALCL (n = 41). Each course of SGN‐30 comprised 6 weekly intravenous infusions, followed by a 2‐week treatment‐free period. Patients had received a median of 3 (range 1–5) prior regimens of chemotherapy or systemic therapy. The initial 40 patients received 6 mg/kg weekly; the latter 39 patients received 12 mg/kg weekly. In the ALCL group, two patients achieved a complete response and five additional patients achieved a partial response, with response durations ranging from 27 to 1460+ d. No objective responses were observed in the HL group; however, 11 patients (29%) had stable disease (duration 62–242 days). Although adverse events were common, most were mild or moderate, and no specific pattern of adverse events was observed in either disease group. These results demonstrate that weekly administration of SGN‐30 is safe, with modest clinical activity in patients with ALCL.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1
ISSN:	0007-1048 1365-2141 1365-2141
DOI:	10.1111/j.1365-2141.2009.07740.x